Opendata, web and dolomites

STRATIFY SIGNED

Diagnostic autoantibody assay to stratify bone marrow failure diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STRATIFY project word cloud

Explore the words cloud of the STRATIFY project. It provides you a very rough idea of what is the project "STRATIFY" about.

simultaneous    underlying    innovation    laboratory    diagnostic    exclusion    heterogenous    destroyed    constitute    blood    anaemia    group    diseases    genetic    takes    reveal    unexplained    introducing    companies    confirming    red    tests    companion    aplastic    acquired    threatening    clinical    vast    personalised    elderly    proper    erc    discovery    bone    serious    thousands    pathogenesis    pharma    cells    defective    misdiagnosis    savings    subset    lives    machines    autoantibody    clinicians    accuracy    made    options    reagent    screening    actions    samples    leukopenia    time    therapy    inherently    syndromes    marrow    validity    kit    diagnosis    producing    patients    positivity    follows    manifest    stem    serology    believe    suggesting    cog    inexpensive    pathology    background    white    healthcare    lies    carry    potentially    protein    rare    difficulties    bmfs    therapies    haematological    commercialisation    preliminary    lack    inappropriate    hundreds    aa    poc    life   

Project "STRATIFY" data sheet

The following table provides information about the project.

Coordinator
HELSINGIN YLIOPISTO 

Organization address
address: YLIOPISTONKATU 3
city: HELSINGIN YLIOPISTO
postcode: 14
website: www.helsinki.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) coordinator 150˙000.00

Map

 Project objective

Bone marrow failure syndromes (BMFS) such as aplastic anaemia (AA) are a heterogenous group of rare diseases that manifest as loss of red and white blood cells. In these potentially life-threatening diseases, blood producing stem cells may be inherently defective or become destroyed due to acquired cause. Diagnostic difficulties of BMFS constitute a significant clinical problem as the diagnosis takes long, and misdiagnosis may lead to inappropriate management with serious side effects.

In our ERC-CoG project we made an exciting discovery and identified a novel autoantibody in AA patients’ blood samples. Autoantibody positivity defined a distinct group of patients with similar genetic background suggesting common pathogenesis. Our preliminary results show that the autoantibody analysis has great potential to reveal cases of AA and define a subset of other BMFS patients with similar underlying pathology that currently lack proper diagnosis. Furthermore, vast commercialisation potential lies in introducing it as an exclusion laboratory test in patients with unexplained anaemia or leukopenia (common problems in elderly). The improved diagnostic accuracy and the targeted personalised therapy that follows has the potential to impact the lives of hundreds of thousands of patients over time and bring simultaneous healthcare savings. Further, understanding of the role of target protein of the autoantibody in bone marrow failure may lead to targeted therapies in the future.

We believe that the test can be developed as an inexpensive reagent kit to be used in serology machines for autoantibody screening. In order to improve the commercialisation potential, we will carry out 1) Technology PoC for confirming the approach validity, and 2) Pre-commercialisation actions for evaluating the best commercialisation options for bringing the innovation to clinicians managing haematological patients and for pharma companies as companion diagnostic tests together with their therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STRATIFY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STRATIFY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

NeuroMag (2019)

The Neurological Basis of the Magnetic Sense

Read More  

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More